Tags : Motegrity

Shire’s Motegrity (prucalopride) Receives FDA Approval for Chronic Idiopathic Constipation

Vartika Singh December 17, 2018

Shots: The approval is based on six trials assessing Motegrity vs PBO in 2,484 patients with Chronic Idiopathic Constipation (CIC) in adults P-III study results: normalization of BM frequency (19-38% […]readmore

Tags : Motegrity

Shire’s Motegrity (prucalopride) Receives FDA Approval for Chronic Idiopathic Constipation

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Motegrity

Shire’s Motegrity (prucalopride) Receives FDA Approval for Chronic Idiopathic Constipation

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company